Vanda Pharmaceuticals to Announce First Quarter 2025 Financial Results on May 7, 2025

5/2/25 8:46:00 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $VNDA alert in real time by email

Conference Call and Webcast to Follow

WASHINGTON, May 2, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced it will release results for the first quarter 2025 on Wednesday, May 7, 2025, after the market closes.

Vanda will host a conference call at 4:30 PM ET on Wednesday, May 7, 2025, during which management will discuss the first quarter 2025 financial results and other corporate activities. To participate in the conference call, please dial 1-800-715-9871 (domestic) or 1-646-307-1963 (international) and use passcode 9941754.

The conference call will be broadcast simultaneously and archived on Vanda's website, www.vandapharma.com. Investors should go to the website at least 15 minutes early to register, download, and install any necessary audio software.

A replay of the call will be available on Wednesday, May 7, 2025, beginning at 8:30 PM ET and will be accessible until Wednesday, May 14, 2025, at 11:59 PM ET. The replay call-in number is 1-800-770-2030 for domestic callers and 1-609-800-9909 for international callers. The passcode number is 9941754.

About Vanda Pharmaceuticals Inc.

Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com and follow us on X @vandapharma.

Corporate Contact:

Kevin Moran

Senior Vice President, Chief Financial Officer and Treasurer

Vanda Pharmaceuticals Inc.

202-734-3400

[email protected]

Jim Golden / Jack Kelleher / Dan Moore

Collected Strategies

[email protected]

View original content to download multimedia:https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-to-announce-first-quarter-2025-financial-results-on-may-7-2025-302445033.html

SOURCE Vanda Pharmaceuticals Inc.

Get the next $VNDA alert in real time by email

Date

Price Target

Rating

Analyst

10/31/2024

$18.00

Buy

H.C. Wainwright

7/11/2024

$11.00

Overweight

Cantor Fitzgerald

2/25/2022

$24.00 → $12.00

Buy → Hold

Jefferies

Vanda Pharmaceuticals to Announce First Quarter 2025 Financial Results on May 7, 2025

5/2/25 8:46:00 AM ET

$VNDA

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $VNDA alert in real time by email

Conference Call and Webcast to Follow

About Vanda Pharmaceuticals Inc.

Corporate Contact:

Kevin Moran

Senior Vice President, Chief Financial Officer and Treasurer

Vanda Pharmaceuticals Inc.

202-734-3400

[email protected]

Jim Golden / Jack Kelleher / Dan Moore

Collected Strategies

[email protected]

View original content to download multimedia:https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-to-announce-first-quarter-2025-financial-results-on-may-7-2025-302445033.html

SOURCE Vanda Pharmaceuticals Inc.

Get the next $VNDA alert in real time by email

Date

Price Target

Rating

Analyst

10/31/2024

$18.00

Buy

H.C. Wainwright

7/11/2024

$11.00

Overweight

Cantor Fitzgerald

2/25/2022

$24.00 → $12.00

Buy → Hold

Jefferies

Vanda Pharmaceuticals to Announce First Quarter 2025 Financial Results on May 7, 2025

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for
$VNDA

Vanda Pharmaceuticals to Announce First Quarter 2025 Financial Results on May 7, 2025

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for
$VNDA

$VNDA
FDA approvals

FDA Approval for PONVORY issued to VANDA PHARMS INC

FDA Approval for PONVORY issued to VANDA PHARMS INC

FDA Approval for FANAPT issued to VANDA PHARMS INC

$VNDA
Analyst Ratings

H.C. Wainwright initiated coverage on Vanda Pharma with a new price target

Cantor Fitzgerald initiated coverage on Vanda Pharma with a new price target

Vanda Pharmaceuticals downgraded by Jefferies with a new price target

$VNDA
Insider Trading

President and CEO Polymeropoulos Mihael Hristos bought $41,500 worth of shares (10,000 units at $4.15), increasing direct ownership by 0.43% to 2,335,731 units (SEC Form 4)

Director Mitchell Stephen Ray sold $32,130 worth of shares (7,000 units at $4.59), decreasing direct ownership by 7% to 97,082 units (SEC Form 4)

Director Mitchell Stephen Ray was granted 59,225 shares, increasing direct ownership by 132% to 104,082 units (SEC Form 4)

$VNDA
Insider Purchases

President and CEO Polymeropoulos Mihael Hristos bought $41,500 worth of shares (10,000 units at $4.15), increasing direct ownership by 0.43% to 2,335,731 units (SEC Form 4)

President and CEO Polymeropoulos Mihael Hristos bought $43,995 worth of shares (10,000 units at $4.40), increasing direct ownership by 0.43% to 2,325,731 units (SEC Form 4)

President and CEO Polymeropoulos Mihael Hristos bought $84,472 worth of shares (20,000 units at $4.22), increasing direct ownership by 0.87% to 2,315,731 units (SEC Form 4)

$VNDA
Press Releases

Vanda Seeks FDA Commissioner Review of Outgoing CDER Director's Decision to Uphold Approval of Two Generic Versions of Hetlioz®

In a Major Win for Vanda, a Federal Appeals Court Overturns FDA's Order Denying Approval of Hetlioz for the Treatment of Jet Lag Disorder

Vanda Pharmaceuticals Reports Second Quarter 2025 Financial Results

$VNDA
SEC Filings

SEC Form 10-Q filed by Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form SCHEDULE 13G filed by Vanda Pharmaceuticals Inc.

$VNDA
Financials

$VNDA
Leadership Updates

$VNDA
Large Ownership Changes

Vanda Pharmaceuticals Reports Second Quarter 2025 Financial Results

Vanda Pharmaceuticals to Announce Second Quarter 2025 Financial Results on July 31, 2025

Vanda Pharmaceuticals Reports First Quarter 2025 Financial Results

Vanda Pharmaceuticals Appoints Dr. Tage Honoré to its Board of Directors

SEC Form SC 13G/A filed by Vanda Pharmaceuticals Inc. (Amendment)

SEC Form SC 13G/A filed by Vanda Pharmaceuticals Inc. (Amendment)

SEC Form SC 13G/A filed by Vanda Pharmaceuticals Inc. (Amendment)

Vanda Pharmaceuticals to Announce First Quarter 2025 Financial Results on May 7, 2025

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for $VNDA

Vanda Pharmaceuticals to Announce First Quarter 2025 Financial Results on May 7, 2025

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for $VNDA

$VNDA FDA approvals

FDA Approval for PONVORY issued to VANDA PHARMS INC

FDA Approval for PONVORY issued to VANDA PHARMS INC

FDA Approval for FANAPT issued to VANDA PHARMS INC

$VNDA Analyst Ratings

H.C. Wainwright initiated coverage on Vanda Pharma with a new price target

Cantor Fitzgerald initiated coverage on Vanda Pharma with a new price target

Vanda Pharmaceuticals downgraded by Jefferies with a new price target

$VNDA Insider Trading

President and CEO Polymeropoulos Mihael Hristos bought $41,500 worth of shares (10,000 units at $4.15), increasing direct ownership by 0.43% to 2,335,731 units (SEC Form 4)

Director Mitchell Stephen Ray sold $32,130 worth of shares (7,000 units at $4.59), decreasing direct ownership by 7% to 97,082 units (SEC Form 4)

Director Mitchell Stephen Ray was granted 59,225 shares, increasing direct ownership by 132% to 104,082 units (SEC Form 4)

$VNDA Insider Purchases

President and CEO Polymeropoulos Mihael Hristos bought $41,500 worth of shares (10,000 units at $4.15), increasing direct ownership by 0.43% to 2,335,731 units (SEC Form 4)

President and CEO Polymeropoulos Mihael Hristos bought $43,995 worth of shares (10,000 units at $4.40), increasing direct ownership by 0.43% to 2,325,731 units (SEC Form 4)

President and CEO Polymeropoulos Mihael Hristos bought $84,472 worth of shares (20,000 units at $4.22), increasing direct ownership by 0.87% to 2,315,731 units (SEC Form 4)

$VNDA Press Releases

Vanda Seeks FDA Commissioner Review of Outgoing CDER Director's Decision to Uphold Approval of Two Generic Versions of Hetlioz®

In a Major Win for Vanda, a Federal Appeals Court Overturns FDA's Order Denying Approval of Hetlioz for the Treatment of Jet Lag Disorder

Vanda Pharmaceuticals Reports Second Quarter 2025 Financial Results

$VNDA SEC Filings

SEC Form 10-Q filed by Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form SCHEDULE 13G filed by Vanda Pharmaceuticals Inc.

$VNDA Financials

$VNDA Leadership Updates

$VNDA Large Ownership Changes

Vanda Pharmaceuticals Reports Second Quarter 2025 Financial Results

Vanda Pharmaceuticals to Announce Second Quarter 2025 Financial Results on July 31, 2025

Vanda Pharmaceuticals Reports First Quarter 2025 Financial Results

Vanda Pharmaceuticals Appoints Dr. Tage Honoré to its Board of Directors

SEC Form SC 13G/A filed by Vanda Pharmaceuticals Inc. (Amendment)

SEC Form SC 13G/A filed by Vanda Pharmaceuticals Inc. (Amendment)

SEC Form SC 13G/A filed by Vanda Pharmaceuticals Inc. (Amendment)

Recent Analyst Ratings for
$VNDA

Recent Analyst Ratings for
$VNDA

$VNDA
FDA approvals

$VNDA
Analyst Ratings

$VNDA
Insider Trading

$VNDA
Insider Purchases

$VNDA
Press Releases

$VNDA
SEC Filings

$VNDA
Financials

$VNDA
Leadership Updates

$VNDA
Large Ownership Changes